NeurAxis Highlights Strength of its Board of Directors

Aug 24, 2023 | Press Releases

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

Aug 22, 2023 | Press Releases

CARMEL, Ind., Aug. 22, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

Aug 17, 2023 | Press Releases

CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023

Aug 15, 2023 | Press Releases

CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin

Aug 10, 2023 | Press Releases

CARMEL, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis Announces Pricing of Initial Public Offering

Aug 9, 2023 | Press Releases

CARMEL, Ind., Aug. 09, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...